News & Updates

In the second interim analysis of the PEARLS/KEYNOTE-091 study, adjuvant pembrolizumab monotherapy provided a clinically meaningful improvement in disease-free survival (DFS) in individuals with stage IB–IIIA non-small cell lung cancer (NSCLC) after complete resection and adjuvant chemotherapy (CT).

New drug applications approved by US FDA as of 16 - 30 November 2022 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

There appears to be low to no metastatic potential for melanocytic tumours of uncertain malignant potential (MELTUMP) and superficial atypical melanocytic proliferations of uncertain significance (SAMPUS), a recent study has found.

Patients with sporadic ampullary tumours more commonly have colorectal polyps or neoplasia than healthy controls, a recent study has found.

A study by the Chinese University of Hong Kong (CUHK) has found age-specific differences in drug responses and new gene-drug interactions in paediatric acute myeloid leukaemia (AML).

Fruquintinib, a highly selective and potent oral tyrosine kinase inhibitor of VEGFR*-1, -2, and -3, significantly improves overall survival (OS) in heavily pretreated patients with metastatic colorectal cancer (mCRC), according to the FRESCO-2** trial presented at ESMO 2022.